• Na Liu, Catherine Yen, Zhao-yin Fang, Jacqueline E Tate, Baoming Jiang, Umesh D Parashar, Guang Zeng, and Zhao-jun Duan.
• Department of Viral Diarrhea, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control, Beijing, China.
• Vaccine. 2012 Nov 6; 30 (48): 6940-5.

IntroductionTwo rotavirus vaccines have been licensed globally since 2006. In China, only a lamb rotavirus vaccine is licensed and several new rotavirus vaccines are in development. Data regarding the projected health impact and cost-effectiveness of vaccination of children in China against rotavirus will assist policy makers in developing recommendations for vaccination.MethodsUsing a Microsoft Excel model, we compared the national health and economic burden of rotavirus disease in China with and without a vaccination program. Model inputs included 2007 data on burden and cost of rotavirus outcomes (deaths, hospitalizations, outpatient visits), projected vaccine efficacy, coverage, and cost. Cost-effectiveness was measured in US dollars per disability-adjusted life-year (DALY) and US dollars per life saved.ResultsA 2-dose rotavirus vaccination program could annually avert 3013 (62%) deaths, 194,794 (59%) hospitalizations and 1,333,356 (51%) outpatient visits associated with rotavirus disease in China. The medical break-even price of the vaccine is $1.19 per dose. From a societal perspective, a vaccination program would be highly cost-effective in China at the vaccine price of $2.50 to $5 per dose, and be cost-effective at the price of $10 to $20 per dose.ConclusionsA national rotavirus vaccination program could be a cost-effective measure to effectively reduce deaths, hospitalizations, and outpatient visits due to rotavirus disease in China.Copyright © 2012 Elsevier Ltd. All rights reserved.

23 keywords...

hide…